Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses ...

Senior author and NYU Assistant Professor Dr Karan Chhabra on larger studies to address drug efficacy and who could do better ...

OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

NCSCM study shows restored mangroves in Adyar Estuary store high carbon levels, aiding climate change mitigation efforts.